微創機器人-B(02252.HK)預期2024年收入同比增長約145%至155%
格隆匯3月3日丨微創機器人-B(02252.HK)公告,基於對集團截至2024年12月31止年度("報告期間")未經審覈綜合管理賬目及董事會現時可獲得數據的初步評估及分析,董事會預期公司報告期間的收入較截至2023年12月31日止年度同比增長約145%至155%,該收入增加乃得益於國內外市場銷售均呈現出強勁的增長趨勢。
1.國內市場深耕細作,圖邁腔鏡手術機器人繼續保持同類產品市佔率第一,R-One血管介入手術機器人獲批上市後獲得市場認可,並實現商業化新突破;2.海外方面,圖邁海外市場探索首年不僅拓展了亞洲、非洲、拉美等新興市場,更在歐洲高端市場實現銷售突破,海外商業化訂單已超過二十臺,並實現十餘臺商業化裝機;鴻鵠骨科手術機器人的海外銷售繼續保持高速增長,全球訂單超過二十臺,裝機量同比實現翻倍增長。
董事會預計集團於截至2024年12月31日止年度將錄得經調整淨虧損介乎於人民幣435百萬元至人民幣521百萬元(2023年12月31日止年度:人民幣869百萬元),該虧損減少乃主要歸功於(i)營業收入快速增長,以及(ii)降本增效多措並舉下,營運費用的大幅下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.